Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXAS
- CUSIP: 30063P10
- Web: www.exactsciences.com
Capitalization:- Market Cap: $5.47 billion
- Outstanding Shares: 119,096,000
Average Prices:- 50 Day Moving Avg: $40.21
- 200 Day Moving Avg: $32.94
- 52 Week Range: $13.05 - $46.15
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -59.69
- P/E Growth: -1.70
Sales & Book Value:- Annual Revenue: $169.37 million
- Price / Sales: 32.32
- Book Value: $4.54 per share
- Price / Book: 10.12
Profitability:- EBIDTA: ($129,740,000.00)
- Net Margins: -83.08%
- Return on Equity: -36.36%
- Return on Assets: -32.85%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 16.82%
- Quick Ratio: 16.42%
Misc:- Average Volume: 1.72 million shs.
- Beta: 0.75
- Short Ratio: 7.98
Frequently Asked Questions for Exact Sciences Corporation (NASDAQ:EXAS)
What is Exact Sciences Corporation's stock symbol?
Exact Sciences Corporation trades on the NASDAQ under the ticker symbol "EXAS."
How were Exact Sciences Corporation's earnings last quarter?
Exact Sciences Corporation (NASDAQ:EXAS) announced its quarterly earnings data on Tuesday, July, 25th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.10. The firm earned $57.65 million during the quarter, compared to analysts' expectations of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. View Exact Sciences Corporation's Earnings History.
When will Exact Sciences Corporation make its next earnings announcement?
Where is Exact Sciences Corporation's stock going? Where will Exact Sciences Corporation's stock price be in 2017?
13 brokerages have issued 1-year price targets for Exact Sciences Corporation's stock. Their forecasts range from $28.00 to $50.00. On average, they anticipate Exact Sciences Corporation's share price to reach $41.69 in the next twelve months. View Analyst Ratings for Exact Sciences Corporation.
What are analysts saying about Exact Sciences Corporation stock?
Here are some recent quotes from research analysts about Exact Sciences Corporation stock:
- 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (8/4/2017)
- 2. Cowen and Company analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)
Who are some of Exact Sciences Corporation's key competitors?
Some companies that are related to Exact Sciences Corporation include Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA) and Ligand Pharmaceuticals Incorporated (LGND).
Who are Exact Sciences Corporation's key executives?
Exact Sciences Corporation's management team includes the folowing people:
- Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer
- Jeffrey Thomas Elliott, Chief Financial Officer
- Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director
- Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer
- D. Scott Coward, Senior Vice President, General Counsel, Secretary
- David A. Thompson, Lead Independent Director
- Thomas D. Carey, Independent Director
- James E. Doyle, Independent Director
- John A. Fallon M.D., Independent Director
- Daniel J. Levangie, Independent Director
Who owns Exact Sciences Corporation stock?
Exact Sciences Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.94%), BlackRock Inc. (5.78%), State Street Corp (3.50%), JPMorgan Chase & Co. (3.14%), William Blair Investment Management LLC (2.63%) and Gilder Gagnon Howe & Co. LLC (2.63%). Company insiders that own Exact Sciences Corporation stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for Exact Sciences Corporation.
Who sold Exact Sciences Corporation stock? Who is selling Exact Sciences Corporation stock?
Exact Sciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Voya Investment Management LLC, William Blair Investment Management LLC, FIL Ltd, State Street Corp, Broadview Advisors LLC, UBS Asset Management Americas Inc. and Elk Creek Partners LLC. Company insiders that have sold Exact Sciences Corporation stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for Exact Sciences Corporation.
Who bought Exact Sciences Corporation stock? Who is buying Exact Sciences Corporation stock?
Exact Sciences Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Lord Abbett & CO. LLC, Victory Capital Management Inc., Vanguard Group Inc., Green Valley Investors LLC, FMR LLC, Renaissance Technologies LLC and Canada Pension Plan Investment Board. Company insiders that have bought Exact Sciences Corporation stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for Exact Sciences Corporation.
How do I buy Exact Sciences Corporation stock?
Shares of Exact Sciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exact Sciences Corporation's stock price today?
One share of Exact Sciences Corporation stock can currently be purchased for approximately $45.96.
MarketBeat Community Rating for Exact Sciences Corporation (NASDAQ EXAS)MarketBeat's community ratings are surveys of what our community members think about Exact Sciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Exact Sciences Corporation (NASDAQ:EXAS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.77) |
| Consensus Price Target: | $41.69 (9.29% downside) |
Analysts' Ratings History for Exact Sciences Corporation (NASDAQ:EXAS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Leerink Swann | Reiterated Rating | Outperform -> Outperform | $45.00 -> $50.00 | High |  |
| 9/7/2017 | Canaccord Genuity | Reiterated Rating | Buy | $45.00 | Low | |
| 7/26/2017 | Bank of America Corporation | Reiterated Rating | Buy | | High | |
| 7/26/2017 | Roth Capital | Boost Price Target | Buy | $40.00 -> $46.00 | High | |
| 7/26/2017 | Craig Hallum | Reiterated Rating | Buy | $41.00 -> $46.00 | High | |
| 7/26/2017 | Lake Street Capital | Boost Price Target | Hold -> Hold | $30.00 -> $41.00 | Medium | |
| 7/17/2017 | BTIG Research | Reiterated Rating | Buy | $35.00 -> $45.00 | Low | |
| 7/7/2017 | Benchmark Co. | Set Price Target | Buy | $50.00 | Low | |
| 6/7/2017 | Stephens | Set Price Target | Hold | $28.00 | Medium | |
| 6/1/2017 | Robert W. Baird | Reiterated Rating | Outperform | $40.00 | Low | |
| 6/1/2017 | Jefferies Group LLC | Set Price Target | Buy | $35.00 | Medium | |
| 5/31/2017 | Cowen and Company | Reiterated Rating | Outperform | $45.00 | High | |
| 5/1/2017 | Goldman Sachs Group, Inc. (The) | Set Price Target | Neutral | $21.00 -> $33.00 | Medium | |
| 7/27/2016 | Mizuho | Boost Price Target | Neutral | $10.00 -> $15.00 | N/A | |
| 7/15/2016 | William Blair | Reiterated Rating | Outperform | $29.00 | N/A | |
| 10/30/2015 | Wedbush | Lower Price Target | | $7.00 -> $6.50 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)Earnings History by Quarter for Exact Sciences Corporation (NASDAQ EXAS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | ($0.31) | | | | | N/A | |
| 7/25/2017 | Q2 2017 | ($0.37) | ($0.27) | $47.73 million | $57.65 million | View | N/A | |
| 4/27/2017 | Q1 2017 | ($0.41) | ($0.32) | $37.38 million | $48.36 million | View | N/A | |
| 2/21/2017 | Q416 | ($0.39) | ($0.34) | $32.53 million | $35.24 million | View | Listen | |
| 10/26/2016 | Q316 | ($0.43) | ($0.36) | $25.24 million | $28.10 million | View | Listen | |
| 7/26/2016 | Q216 | ($0.55) | ($0.46) | $18.54 million | $21.20 million | View | Listen | |
| 5/3/2016 | Q116 | ($0.52) | ($0.49) | $15.17 million | $14.80 million | View | N/A | |
| 2/24/2016 | Q415 | ($0.47) | ($0.41) | $14.96 million | $14.40 million | View | Listen | |
| 10/29/2015 | Q315 | ($0.44) | ($0.45) | $12.56 million | $12.60 million | View | Listen | |
| 7/20/2015 | Q215 | ($0.45) | ($0.44) | $7.96 million | $8.10 million | View | Listen | |
| 5/4/2015 | Q115 | ($0.41) | ($0.40) | $4.11 million | $4.30 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.39) | ($0.38) | $19.90 million | $1.15 million | View | N/A | |
| 10/27/2014 | Q314 | ($0.34) | ($0.39) | $0.13 million | | View | Listen | |
| 7/22/2014 | Q214 | ($0.25) | ($0.24) | $0.03 million | | View | N/A | |
| 5/1/2014 | Q114 | ($0.19) | ($0.23) | $0.40 million | $0.30 million | View | N/A | |
| 2/20/2014 | Q413 | ($0.19) | ($0.17) | $1.02 million | $1.00 million | View | N/A | |
| 10/29/2013 | Q313 | ($0.18) | ($0.16) | $1.02 million | $1.00 million | View | N/A | |
| 7/23/2013 | Q2 2013 | ($0.18) | ($0.19) | $1.02 million | $1.00 million | View | N/A | |
| 5/1/2013 | Q1 2013 | ($0.20) | ($0.17) | $1.02 million | $1.00 million | View | N/A | |
| 2/20/2013 | Q4 2012 | ($0.18) | ($0.22) | $1.04 million | $1.00 million | View | N/A | |
| 10/30/2012 | Q312 | ($0.21) | ($0.21) | $1.03 million | $1.04 million | View | N/A | |
| 7/25/2012 | | ($0.20) | ($0.26) | | | View | N/A | |
| 5/1/2012 | | ($0.18) | ($0.19) | | | View | N/A | |
| 2/23/2012 | | ($0.17) | ($0.18) | | | View | N/A | |
| 11/3/2011 | | ($0.15) | ($0.15) | | | View | N/A | |
| 8/2/2011 | | ($0.10) | ($0.13) | | | View | N/A | |
| 5/3/2011 | | ($0.09) | ($0.08) | | | View | N/A | |
| 2/15/2011 | | ($0.08) | ($0.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Exact Sciences Corporation (NASDAQ:EXAS)2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.07)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.44) | ($0.40) | ($0.42) |
| Q2 2017 | 4 | ($0.41) | ($0.33) | ($0.38) |
| Q3 2017 | 5 | ($0.35) | ($0.28) | ($0.33) |
| Q4 2017 | 5 | ($0.36) | ($0.30) | ($0.34) |
| Q1 2018 | 3 | ($0.33) | ($0.29) | ($0.32) |
| Q2 2018 | 3 | ($0.33) | ($0.25) | ($0.28) |
| Q3 2018 | 3 | ($0.32) | ($0.21) | ($0.25) |
| Q4 2018 | 3 | ($0.31) | ($0.14) | ($0.22) |
| Q1 2019 | 1 | ($0.14) | ($0.14) | ($0.14) |
(Data provided by Zacks Investment Research)
Dividend History for Exact Sciences Corporation (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exact Sciences Corporation (NASDAQ:EXAS)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 85.22%
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/5/2017 | Graham Peter Lidgard | Insider | Sell | 75,683 | $40.81 | $3,088,623.23 | |
| 9/1/2017 | Graham Peter Lidgard | Insider | Sell | 45,775 | $41.49 | $1,899,204.75 | |
| 8/17/2017 | Thomas D Carey | Director | Buy | 2,500 | $37.71 | $94,275.00 | |
| 7/31/2017 | Jeffrey Thomas Elliott | CFO | Sell | 5,846 | $39.41 | $230,390.86 | |
| 7/3/2017 | D Scott Coward | SVP | Sell | 1,987 | $35.21 | $69,962.27 | |
| 4/3/2017 | D Scott Coward | SVP | Sell | 1,543 | $23.74 | $36,630.82 | |
| 3/13/2017 | D Scott Coward | SVP | Sell | 1,983 | $21.16 | $41,960.28 | |
| 3/13/2017 | Kevin T Conroy | Insider | Sell | 12,059 | $21.16 | $255,168.44 | |
| 3/13/2017 | Maneesh Arora | COO | Sell | 5,574 | $21.16 | $117,945.84 | |
| 2/27/2017 | D Scott Coward | SVP | Sell | 7,046 | $21.48 | $151,348.08 | |
| 2/27/2017 | Graham Peter Lidgard | Insider | Sell | 8,668 | $21.51 | $186,448.68 | |
| 2/27/2017 | Maneesh Arora | COO | Sell | 11,114 | $21.50 | $238,951.00 | |
| 1/3/2017 | D Scott Coward | SVP | Sell | 1,535 | $13.61 | $20,891.35 | |
| 12/14/2016 | David Thompson | Director | Buy | 10,000 | $13.84 | $138,400.00 | |
| 11/15/2016 | Kevin T Conroy | Insider | Sell | 600,000 | $17.46 | $10,476,000.00 | |
| 11/15/2016 | Maneesh Arora | COO | Sell | 562,932 | $17.46 | $9,828,792.72 | |
| 9/1/2016 | Lionel Sterling | Director | Buy | 5,000 | $18.10 | $90,500.00 | |
| 8/3/2016 | Katherine S Zanotti | Director | Buy | 3,380 | $17.93 | $60,603.40 | |
| 7/26/2016 | Graham Peter Lidgard | Insider | Sell | 7,383 | $14.82 | $109,416.06 | |
| 7/26/2016 | Maneesh Arora | COO | Sell | 7,359 | $14.82 | $109,060.38 | |
| 4/1/2016 | D Scott Coward | SVP | Sell | 1,685 | $6.62 | $11,154.70 | |
| 3/10/2016 | D Scott Coward | SVP | Sell | 2,175 | $6.05 | $13,158.75 | |
| 3/10/2016 | Graham Peter Lidgard | Insider | Sell | 3,041 | $6.05 | $18,398.05 | |
| 3/10/2016 | Maneesh Arora | COO | Sell | 4,042 | $6.05 | $24,454.10 | |
| 3/8/2016 | James Edward Doyle | Director | Buy | 5,000 | $6.43 | $32,150.00 | |
| 3/3/2016 | Katherine S Napier | Director | Buy | 3,775 | $5.38 | $20,309.50 | |
| 3/1/2016 | Kevin T Conroy | CEO | Buy | 50,000 | $5.00 | $250,000.00 | |
| 2/26/2016 | Kevin T Conroy | CEO | Sell | 6,895 | $5.81 | $40,059.95 | |
| 2/25/2016 | Graham Peter Lidgard | Insider | Sell | 2,997 | $5.52 | $16,543.44 | |
| 2/25/2016 | Maneesh Arora | COO | Sell | 4,099 | $5.52 | $22,626.48 | |
| 2/23/2016 | Graham Peter Lidgard | Insider | Sell | 2,411 | $6.39 | $15,406.29 | |
| 2/23/2016 | Kevin T Conroy | CEO | Sell | 6,866 | $6.39 | $43,873.74 | |
| 2/23/2016 | Maneesh Arora | COO | Sell | 2,556 | $6.39 | $16,332.84 | |
| 1/11/2016 | David Thompson | Director | Buy | 15,000 | $6.99 | $104,850.00 | |
| 2/26/2015 | Graham Peter Lidgard | Director | Sell | 3,938 | $23.44 | $92,306.72 | |
| 2/26/2015 | Kevin T Conroy | CEO | Sell | 8,425 | $23.44 | $197,482.00 | |
| 2/26/2015 | Maneesh Arora | COO | Sell | 3,895 | $23.44 | $91,298.80 | |
| 2/24/2015 | Graham Peter Lidgard | Director | Sell | 4,037 | $22.90 | $92,447.30 | |
| 2/24/2015 | Kevin T Conroy | CEO | Sell | 9,798 | $22.90 | $224,374.20 | |
| 2/24/2015 | Maneesh Arora | COO | Sell | 2,995 | $22.90 | $68,585.50 | |
| 1/2/2015 | Graham Peter Lidgard | Insider | Sell | 3,363 | $26.72 | $89,859.36 | |
| 1/2/2015 | Kevin T Conroy | CEO | Sell | 9,484 | $26.72 | $253,412.48 | |
| 1/2/2015 | Maneesh Arora | COO | Sell | 2,495 | $26.72 | $66,666.40 | |
| 10/29/2014 | Graham Peter Lidgard | Insider | Sell | 8,015 | $24.68 | $197,810.20 | |
| 7/25/2014 | Graham Peter Lidgard | VP | Sell | 11,081 | $15.99 | $177,185.19 | |
| 7/25/2014 | Kevin T Conroy | CEO | Sell | 11,336 | $15.99 | $181,262.64 | |
| 7/25/2014 | Maneesh Arora | COO | Sell | 9,291 | $15.99 | $148,563.09 | |
| 5/5/2014 | William Megan | SVP | Buy | 10,000 | $11.79 | $117,900.00 | |
| 2/24/2014 | Graham Peter Lidgard | VP | Sell | 3,160 | $14.07 | $44,461.20 | |
| 2/24/2014 | Kevin Conroy | CEO | Sell | 8,708 | $14.07 | $122,521.56 | |
| 2/24/2014 | Maneesh Arora | COO | Sell | 2,662 | $14.07 | $37,454.34 | |
| 1/2/2014 | Graham Peter Lidgard | VP | Sell | 10,288 | $11.96 | $123,044.48 | |
| 1/2/2014 | Kevin Conroy | CEO | Sell | 26,379 | $11.96 | $315,492.84 | |
| 1/2/2014 | Maneesh Arora | COO | Sell | 8,627 | $11.96 | $103,178.92 | |
| 10/28/2013 | Graham Peter Lidgard | VP | Sell | 7,430 | $11.07 | $82,250.10 | |
| 9/20/2013 | Sally Crawford | Director | Sell | 25,000 | $12.19 | $304,750.00 | |
| 11/2/2012 | Kevin T Conroy | CEO | Buy | 2,000 | $9.13 | $18,260.00 | |
| 11/2/2012 | Maneesh Arora | CFO | Buy | 1,000 | $9.04 | $9,040.00 | |
| 11/1/2012 | Lionel Sterling | Director | Buy | 5,500 | $9.08 | $49,940.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Exact Sciences Corporation (NASDAQ:EXAS)
Latest Headlines for Exact Sciences Corporation (NASDAQ:EXAS)
| Source: |
|
| Date | Headline |
|---|
 | Today's Research Reports on Trending Tickers: Exact Sciences and Inovio Pharmaceuticals
finance.yahoo.com - September 22 at 8:18 AM |
| Why Exact Sciences Corporation (EXAS) Could Be A Buy
finance.yahoo.com - September 21 at 6:39 PM |
 | Leerink Swann Boosts Exact Sciences Corporation (EXAS) Price Target to $50.00
www.americanbankingnews.com - September 21 at 10:02 AM |
| Analysts Expect Exact Sciences Corporation (EXAS) Will Post Quarterly Sales of $63.81 Million
www.americanbankingnews.com - September 19 at 9:26 AM |
| -$0.31 EPS Expected for Exact Sciences Corporation (EXAS) This Quarter
www.americanbankingnews.com - September 17 at 8:20 AM |
| Head to Head Survey: Matinas BioPharma Holdings (MTNB) and Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - September 15 at 9:02 PM |
 | IWO, CTLT, AZPN, EXAS: Large Outflows Detected at ETF - Nasdaq
www.nasdaq.com - September 12 at 7:21 PM |
| Exact Sciences Corporation (EXAS) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - September 10 at 12:34 AM |
 | Exact Sciences (EXAS) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 4:37 AM |
| EXACT Sciences Co. (EXAS) Insider Graham Peter Lidgard Sells 75,683 Shares
www.americanbankingnews.com - September 7 at 7:22 PM |
| Exact Sciences Corporation (EXAS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 6 at 4:50 PM |
| Insider Selling: Exact Sciences Corporation (EXAS) Insider Sells 45,775 Shares of Stock
www.americanbankingnews.com - September 5 at 7:23 PM |
| Brokerages Expect Exact Sciences Corporation (EXAS) Will Post Quarterly Sales of $63.81 Million
www.americanbankingnews.com - August 31 at 1:58 AM |
| IWO, CTLT, EXAS, PRXL: Large Outflows Detected at ETF - Nasdaq ... - Nasdaq
www.nasdaq.com - August 31 at 12:52 AM |
| Exact Sciences to participate in Baird Global Healthcare Conference
finance.yahoo.com - August 30 at 7:46 PM |
| Brokerages Anticipate Exact Sciences Corporation (EXAS) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - August 29 at 8:30 PM |
| Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)
finance.yahoo.com - August 29 at 6:55 PM |
| Leerink Swann Weighs in on Exact Sciences Corporation's Q3 2017 Earnings (EXAS)
www.americanbankingnews.com - August 28 at 1:40 AM |
| Exact Sciences Corporation (EXAS) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - August 25 at 9:44 PM |
| 3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
finance.yahoo.com - August 25 at 8:05 PM |
| Exact Sciences: On the Way to 24 Million Tests?
finance.yahoo.com - August 24 at 7:45 PM |
| Exact Sciences Corporation (EXAS) Given a $45.00 Price Target at Leerink Swann
www.americanbankingnews.com - August 24 at 1:38 PM |
| Today's Research Reports on Trending Tickers: Ionis Pharmaceuticals Inc. and Exact Sciences Corporation
finance.yahoo.com - August 23 at 11:18 PM |
| Exact Sciences Corporation (EXAS) Director Thomas D. Carey Acquires 2,500 Shares
www.americanbankingnews.com - August 18 at 8:32 PM |
| See what the IHS Markit Score report has to say about Exact Sciences Corp.
finance.yahoo.com - August 15 at 4:52 AM |
| Brokerages Anticipate EXACT Sciences Co. (NASDAQ:EXAS) Will Post Quarterly Sales of $63.42 Million
www.americanbankingnews.com - August 13 at 7:40 AM |
| Exact Sciences Corporation (EXAS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 12 at 4:44 PM |
| Exact Sciences Corporation (EXAS) Short Interest Update
www.americanbankingnews.com - August 12 at 1:44 AM |
| Analysts Expect Exact Sciences Corporation (NASDAQ:EXAS) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - August 11 at 5:11 PM |
 | Better Buy: Exact Sciences Corporation vs. Opko Health
www.fool.com - August 11 at 8:19 AM |
| ETFs with exposure to EXACT Sciences Corp. : August 8, 2017
finance.yahoo.com - August 8 at 6:17 PM |
| Exact Sciences Corporation (NASDAQ:EXAS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 4 at 9:56 PM |
| Exact Sciences CEO Sees Steady Uptick in Cologuard Orders
finance.yahoo.com - August 4 at 6:46 PM |
| Optimistic Takeaways From Exact Sciences Annual Meeting - Seeking Alpha
seekingalpha.com - August 3 at 12:24 AM |
| Here's Why the Best Is Yet to Come for Exact Sciences
finance.yahoo.com - August 2 at 12:12 AM |
| Jeffrey Thomas Elliott Sells 5,846 Shares of Exact Sciences Corporation (EXAS) Stock
www.americanbankingnews.com - August 1 at 7:48 PM |
| VNRX: Large U.S. Study Comes Cheap, Could Support Asymptomatic FDA Filing
finance.yahoo.com - August 1 at 7:09 PM |
| Commit To Buy EXACT Sciences Corp. At $27, Earn 12.6% Using Options
www.nasdaq.com - July 31 at 6:14 PM |
| Equities Analysts Offer Predictions for Exact Sciences Corporation's FY2017 Earnings (EXAS)
www.americanbankingnews.com - July 28 at 9:31 AM |
| Exact Sciences Corporation (NASDAQ:EXAS) Expected to Earn Q3 2017 Earnings of ($0.33) Per Share
www.americanbankingnews.com - July 28 at 7:31 AM |
| Leerink Swann Brokers Decrease Earnings Estimates for Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - July 28 at 7:30 AM |
| Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%
finance.yahoo.com - July 27 at 7:00 PM |
| Research Analysts Set Expectations for Exact Sciences Corporation's FY2019 Earnings (NASDAQ:EXAS)
www.americanbankingnews.com - July 27 at 2:48 PM |
| Exact Sciences Crushes Estimates Again - Seeking Alpha
seekingalpha.com - July 27 at 5:08 AM |
| Exact Sciences: Blowout!
finance.yahoo.com - July 27 at 12:04 AM |
| EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 26, 2017
finance.yahoo.com - July 27 at 12:04 AM |
| Exact Sciences Corporation (NASDAQ:EXAS) Receives "Buy" Rating from Craig Hallum
www.americanbankingnews.com - July 26 at 8:03 PM |
| Exact Sciences Corporation (NASDAQ:EXAS) PT Raised to $45.00
www.americanbankingnews.com - July 26 at 7:27 PM |
| EXACT Sciences' (EXAS) CEO Kevin Conroy on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 26 at 7:04 PM |
| Edited Transcript of EXAS earnings conference call or presentation 25-Jul-17 9:00pm GMT
finance.yahoo.com - July 26 at 7:04 PM |
Exact Sciences Corporation (EXAS) Chart for Friday, September, 22, 2017
